The fi rst whole-genome study of drug-resistant breast cancer in patient-derived xenografts (PDX) in mice produced several major surprises, says Matthew Ellis, MB, BChir, PhD, professor of medicine at Washington University School of Medicine in Saint Louis, MO.
One was the discovery of endocrine-therapy-resistant mutations of the estrogen receptor-1 gene (ESR1), including a translocation and an amplifi cation (Cell Reports 2013; 4:1116-30) . "Understanding these types of mutations is a potential game-changer in medical practice," says Ellis. "Depending on whether ESR1 is wild-type, pointmutated, translocated, or amplifi ed, you could do different treatments."
Another surprise from the study, Ellis says, was the "astonishing" fi delity with which the PDXs refl ected genomic variants found in the original human tumor.
Moreover, that fi delity included "remarkably consistent" allele frequency distributions in the originating tumor and PDXs. "In the competition model we're all brought up on, a rare allele is about to die out or it's about to dominate, but that's not what you see here," he comments. "What that observation suggests is not a competition model; it's a cooperation model, in which somehow minor clones and major clones must be talking to each other to maintain a hierarchy of frequencies."
Findings such as these highlight the potential advantages of PDX models, created from individual patients' tumors, over traditional cell lines and animal models. The ESR1 translocations, for instance, aren't present in the conventional ER-positive cell lines and thus hadn't been detected. "So it really shows the advantage of going to the PDX system and trying to link it directly with patient experiences," says Ellis. "Because we wouldn't have made these discoveries if we carried on studying T47D cells and MCF7 cells for the rest of our lives." PDX models for breast cancer, while slower to emerge than models for some other cancers, such as colon and pancreatic cancers, are now becoming established. "I can only imagine that PDX research will increase massively in signifi cance, and perhaps almost become a mandatory step in drug development," Ellis says.
Among signs of growing acceptance of PDX-based research, "reviewers for both journals and grants are already starting to demand use of these models," says Alana Welm, PhD, associate professor of oncological sciences at Huntsman Cancer Institute at the University of Utah in Salt Lake City. She estimates that her lab has given its PDX models of breast cancer to about 100 labs since publishing a Nature Medicine paper in 2011 (Nat Med 2011; 17:1514-20 
